evipedia.ai
← Back

Mexidol for Health & Longevity

Evidence Review created on 10/11/2026 using AI4L / Opus 5.5

Also known as: Emoxypine Succinate, Emoxypine, Ethylmethylhydroxypyridine Succinate, 2-ethyl-6-methyl-3-hydroxypyridine succinate, EMHPS, Mexidol FORTE 250, Mexicor, Neurox, Mexiprim, Armadin Long, Medomexi, Neuromexol, Metostabil, Mexidant

Motivation

Mexidol is a prescription medicine developed in Russia. Chemically it pairs emoxypine, a molecule related to vitamin B6, with succinic acid, a natural compound cells use to make energy. It is promoted as an antioxidant that shields brain cells when blood flow or oxygen runs short, which has drawn interest from people focused on brain aging and mental performance.

In Russia and neighboring countries it has been prescribed for decades, mainly for reduced blood flow to the brain, including after stroke, and for anxiety. A series of placebo-controlled trials, most of them paid for by the manufacturer, has studied these uses. Outside that region it is unapproved and circulates mainly through online “brain-booster” supplement vendors, so most Western users rely on a research base they cannot easily read or check.

This review examines what the human trials, laboratory studies and safety records show about Mexidol for brain health, mood and healthy aging, how strong and how independent that evidence is, and what a protocol, monitoring plan and risk profile look like for health-focused adults.

Benefits - Risks - Protocol - Conclusion

This section lists overview articles that discuss Mexidol’s pharmacology, clinical use and regulatory position in depth.

Only four items qualified. No relevant content on Mexidol or emoxypine was found from Rhonda Patrick, Peter Attia, Andrew Huberman, Chris Kresser, Life Extension Magazine or Lifespan.io; the drug is little discussed outside Russian-language medicine, so the list was not padded with marginal sources.

Grokipedia

Emoxypine

A general overview of emoxypine and its succinate salt (Mexidol), covering chemistry, approved Russian uses, proposed mechanisms and registered trials; useful orientation, though largely uncritical about evidence quality.

Examine

No Examine article on Mexidol or emoxypine exists. Mexidol is a prescription drug in Russia (Mexidol FORTE 250 prescribing information (Vidal)), and Examine.com does not typically cover prescription medications.

ConsumerLab

No ConsumerLab article on Mexidol or emoxypine exists. Mexidol is a prescription drug in Russia (Mexidol FORTE 250 prescribing information (Vidal)), and ConsumerLab does not typically cover prescription medications.

Systematic Reviews

This section lists the systematic reviews and meta-analyses that include Mexidol.

The principal risk side is unrepresented: no systematic review or meta-analysis of Mexidol’s adverse effects has been published.

Mechanism of Action

Mexidol is the succinate salt of emoxypine, a 3-hydroxypyridine related to vitamin B6. Proposed actions come from both halves (Shchulkin, 2018):

  • Antioxidant action: the pyridine ring neutralizes free radicals, limits lipid peroxidation (oxidative damage to membrane fats) and raises superoxide dismutase (an enzyme that destroys superoxide radicals), partly via Nrf2 (a switch for cellular antioxidant genes).
  • Low-oxygen energy support: succinate can feed succinate dehydrogenase (a mitochondrial energy enzyme) and activates SUCNR1 (a cell-surface succinate sensor), which triggers HIF-1α (a protein coordinating adaptation to low oxygen) (Lukyanova et al., 2018).
  • Neurotransmitter modulation: the label describes enhanced binding at GABA (the brain’s main calming messenger) and benzodiazepine (a sedative drug class) receptor sites (Mexidol FORTE 250 prescribing information (Vidal)); a review proposes inhibition of MAO-A (monoamine oxidase A, an enzyme that breaks down serotonin and dopamine) (Volchegorskii et al., 2023).

A competing view: a computational study found only moderate radical scavenging, mainly via copper binding (Hoa et al., 2022), and injected succinate is cleared quickly in rats with little mitochondrial uptake (Shchulkin et al., 2023).

Pharmacology: oral absorption is rapid; half-life is 2–2.6 hours; liver UGT enzymes (which attach glucuronic acid) yield five urinary metabolites (Mexidol FORTE 250 prescribing information (Vidal)). A review notes rapid spread into tissues, including the brain (Gupta et al., 2022); it has no single high-affinity target. In cells it inhibits, but is not carried by, the drug pump encoded by ABCB1 (a gut and brain efflux gene) (Shchulkin et al., 2023).

Historical Context & Evolution

Mexidol belongs to a family of original Russian 3-hydroxypyridine and succinate drugs that also includes emoxipin (emoxypine without succinate) and reamberin (Volchegorskii et al., 2014). Mexidol was characterized pharmacologically at the Zakusov Institute of Pharmacology in Moscow, whose researchers described anti-ischemic (protecting tissue deprived of blood flow), anxiety-relieving, anticonvulsant and anti-alcohol effects in animals (Voronina, 2009). Its original intended uses were stroke and other disorders of brain blood flow, anxiety, and alcohol withdrawal.

Early clinical support came from small open studies. A first double-blind placebo-controlled trial in acute stroke followed in 2006 (Skvortsova et al., 2006), and larger multicenter trials in stroke and chronic brain ischemia (long-term reduced brain blood flow), sponsored by the manufacturer Pharmasoft, appeared from 2017 to 2025 (Stakhovskaya et al., 2017; Fedin et al., 2021; Shamalov et al., 2025).

Interest for health optimization grew from three directions: its antioxidant and “energy” framing, a rat study reporting longer lifespan (Voronina, 2020), and use by athletes and nootropic (cognitive-enhancer) consumers, which led to its detection as an unauthorized ingredient in Western “brain” supplements (Jędrejko et al., 2023).

Opinion has shifted rather than settled. Claims that the drug lacks placebo-controlled data are now outdated, because such trials exist. What has not changed is that most of them come from one sponsor and nearly all from Russian investigators, and a review from India still calls for more clinical trials of safety and efficacy (Gupta et al., 2022).

Expected Benefits

High 🟩 🟩 🟩

Improved Cognition in Cerebrovascular Disease ⚠️ Conflicted

In chronic brain ischemia and after stroke, 2–3-month courses raised cognitive test scores. Support: Fedin’s double-blind MEMO trial on the Montreal Cognitive Assessment (MoCA, a 30-point memory and thinking test) (Fedin et al., 2021, Pharmasoft-sponsored), Chukanova’s open trial on a similar screening test (Chukanova et al., 2015) and Karpov’s post-stroke trial (Karpov et al., 2022). MoCA did not differ significantly in MIR (Shamalov et al., 2025), a secondary endpoint in acute stroke, or Belkin’s small Pharmasoft-sponsored trial (Belkin et al., 2024). Net reading: a modest benefit, mainly from sponsor-linked teams.

Magnitude: Pooled MoCA difference of 2.06 points versus standard therapy alone across 10 trials, 95% confidence interval (CI, the range likely to contain the true effect) 0.98–3.14 (Zakharov & Vakhnina, 2024); in MEMO the lower 95% CI bound of the difference versus placebo was 1.51 points (Fedin et al., 2021).

Reduced Anxiety and Low Mood ⚠️ Conflicted

In a double-blind placebo-controlled randomized controlled trial (RCT) in alcohol withdrawal, Volchegorskii’s group found faster resolution of clinician-rated but not self-rated anxiety (Volchegorskii et al., 2021). Self-rated anxiety improved versus placebo in Fedin’s MEMO (Fedin et al., 2021) but barely differed in MIR (median −2 versus −1 points) (NCT06437626). Open-label trials reported lower anxiety after brain injury (Belkin et al., 2024) and better depression scores added to SSRIs (selective serotonin reuptake inhibitors, standard antidepressants) (Medvedev et al., 2023). Net reading: clinician-rated improvement is consistent; blinded self-report is mixed.

Magnitude: Hospital Anxiety and Depression Scale anxiety score 2.6 versus 4.4 with standard care alone (p=0.004, p-value: the probability of a difference this large arising by chance; open-label, no placebo) (Belkin et al., 2024); in the withdrawal trial, Mexidol shortened specific clinician-rated anxiety symptoms by 25–50% versus placebo (Volchegorskii et al., 2021).

Less Fatigue (Asthenia)

Asthenia (persistent weakness and fatigue) is a labeled Russian indication (Mexidol FORTE 250 prescribing information (Vidal)). In a randomized open-label trial of 129 adults after COVID-19, Zolotovskaia’s group found that 125 mg three times daily of a generic (Neurox) for 4 weeks reduced fatigue scores only in the treated group (Zolotovskaia et al., 2022). Fedin’s double-blind MEMO trial found less fatigue than placebo on the Multidimensional Fatigue Inventory (MFI-20, a 20–100-point questionnaire) as a secondary outcome (Fedin et al., 2021). No trial has tested healthy adults.

Magnitude: In MEMO, MFI-20 scores fell 8.33 points with Mexidol and 4.80 points with placebo from baseline to day 75; within-group changes, not compared between groups in the registry report (NCT06834490).

Medium 🟩 🟩

Better Functional Recovery After Ischemic Stroke

Added to standard care, an intravenous-then-oral course was associated with less disability after a first ischemic stroke (stroke from a blocked artery) in patients not treated with clot removal. Support comes from two double-blind RCTs from one investigator network (Stakhovskaya, Shamalov), EPICA (Stakhovskaya et al., 2017) and MIR (Shamalov et al., 2025), both sponsored by Pharmasoft with overlapping sites, and from independent cohorts pooled by Voznyuk’s team (Voznyuk et al., 2023). Pooled benefit grew with greater initial deficit.

Magnitude: In MIR, the modified Rankin Scale (mRS, a 0–6 disability score) fell 2.45 points (95% CI 2.23–2.70) with Mexidol versus 2.01 points (1.87–2.25) with placebo, a significant between-group difference (p=0.003); 60% versus 41% reached mRS 0–1 and 16% versus 28% remained disabled (NCT06437626; Mexidol FORTE 250 prescribing information (Vidal)).

Relief of Diabetic Nerve Symptoms

In randomized trials by Volchegorskii’s group, 14 days of intravenous Mexidol 300 mg/day reduced symptoms of diabetic peripheral neuropathy (nerve damage causing numbness, burning and tingling in the feet), versus placebo in one (Volchegorskii et al., 2005) and in a head-to-head comparison with alpha-lipoic acid in another (Volchegorskii et al., 2008). An independent systematic review listed Mexidol among treatments with significant symptom benefit (Çakici et al., 2016). Only intravenous courses were tested.

Magnitude: Lower neuropathic symptom and dysfunction scores than placebo after 14 days of intravenous Mexidol 300 mg/day in diabetic foot syndrome (nerve and blood-vessel damage in the feet from diabetes); the published abstracts report no outcome figure, and the full Russian-language reports are not openly accessible.

Slower Glaucoma Progression

In primary open-angle glaucoma (slow optic-nerve damage that narrows the visual field), Egorov’s Pharmasoft-sponsored placebo-controlled RCT found better visual-field sensitivity and less progression after 14 days of injections then 90 days orally (Egorov et al., 2025). Volchegorskii’s earlier single-blind RCT found visual-field gains that faded within 3 months (Volchegorskii et al., 2012), and Vlasova’s Pharmasoft-sponsored open study found retinal and mitochondrial-enzyme gains at 14 and 56 days (Vlasova et al., 2024). Durable benefit rests on one trial.

Magnitude: Lower probability of progression than placebo (p<0.01) after 14 days of injections followed by 90 days orally in stage II–III primary open-angle glaucoma; the literature reports no outcome figure for the between-group difference.

Better Outcomes in Heart Failure After Myocardial Infarction

In a randomized trial of 100 patients with heart failure after myocardial infarction (heart attack), Sidorenko’s group found that adding ethylmethylhydroxypyridine succinate (Mexidol’s active substance) to conventional therapy lowered complications, deaths and readmissions over 3 years (Sidorenko et al., 2011). It is the only long-term outcome trial, small and not placebo-controlled.

Magnitude: Fewer complications, deaths and readmissions than conventional therapy alone over 3 years after myocardial infarction (randomized, not placebo-controlled); the published abstract reports no outcome figure, and the full Russian-language report is not openly accessible.

Fewer Angina Attacks in Coronary Artery Disease

In coronary artery disease (narrowed heart arteries), adding Mexicor to standard treatment lessened the frequency, duration and severity of monitored myocardial ischemia (heart-muscle oxygen shortage) and stabilized unstable angina (chest pain from reduced heart blood flow) sooner in an open randomized trial by Golikov’s group (Golikov et al., 2004). Kazantsev’s group reported less frequent and milder angina attacks, but its abstract does not describe a comparison group (Kazantsev et al., 2006). No placebo-controlled trial exists.

Magnitude: Less frequent, shorter and milder myocardial ischemia than standard treatment alone in unstable angina (open-label, no placebo); the published abstract reports no outcome figure, and the full Russian-language report is not openly accessible.

Better Blood Pressure Control in Hypertension

In an open randomized trial by Golikov’s group in hypertensive crises (sudden severe blood-pressure surges), adding Mexicor to conventional treatment normalized the 24-hour blood-pressure profile sooner and reduced crisis recurrence (Golikov et al., 2004). In 60 hypertensive patients after acute ischemic stroke, a randomized trial by Mikhin, a co-author of the Golikov trial, found faster systolic and diastolic lowering and a more normal night-time blood-pressure fall with Mexicor added (Mikhin et al., 2008). Both trials were open-label, short and from one research network; no placebo-controlled trial exists.

Magnitude: Hypertensive-crisis recurrence was 2-fold lower than with conventional treatment alone (open-label, no placebo) (Golikov et al., 2004).

Better Blood Sugar Control in Type 2 Diabetes

In a double-blind placebo-controlled RCT of 20 adults with type 2 diabetes, Klebanova’s group found that Mexicor improved fasting glucose, glycated hemoglobin (HbA1c, a roughly 3-month blood sugar average) and insulin resistance (a weakened response to insulin) (Klebanova et al., 2006). An open 16-week randomized trial by Statsenko’s group in coronary disease with diabetes also reported lower insulin resistance (Statsenko et al., 2013). The placebo-controlled evidence rests on one very small trial.

Magnitude: Lower fasting glucose, HbA1c and insulin resistance than placebo in a 20-patient type 2 diabetes trial; the literature reports no outcome figure.

Lower Total and Low-Density Lipoprotein Cholesterol

The label claims cholesterol lowering (Mexidol FORTE 250 prescribing information (Vidal)), and Klebanova’s double-blind placebo-controlled RCT in type 2 diabetes found improved blood lipids (Klebanova et al., 2006). Kazantsev’s coronary-disease study reported lower low-density lipoprotein (LDL, “bad”) cholesterol (Kazantsev et al., 2006), and a narrative review of Russian post-stroke studies reports lower total and LDL cholesterol (Zhuravleva et al., 2020). Placebo-controlled lipid data come from one very small trial.

Magnitude: Improved blood lipids versus placebo in a 20-patient type 2 diabetes trial; the published abstract reports no cholesterol outcome figure, and the full Russian-language report is not openly accessible.

Improved Attention Deficit Hyperactivity Symptoms in Children ⭕️ Not Central to Health & Longevity

In the Pharmasoft-sponsored MEGA RCT of 333 children aged 6–12, 125 mg twice daily for 6 weeks, like once-daily dosing, improved attention deficit hyperactivity disorder (ADHD) rating scores more than placebo (Zavadenko et al., 2022). This bears on childhood attention and behavior, not adult health or longevity, though it shows brain activity at oral doses.

Magnitude: Greater improvement in ADHD rating scores than placebo after 6 weeks of 125 mg twice daily in children aged 6–12 (p=0.000024); the literature reports no between-group outcome figure.

Low 🟩

Physical Performance and Low-Oxygen Tolerance

A review describes use by Russian athletes and cites studies in healthy people suggesting that pyridine–succinate drugs, including Mexidol and the multi-ingredient Cytoflavin, enhance performance (Jędrejko et al., 2024). Evidence is indirect: the review pools Mexidol with related succinate products rather than reporting a Mexidol-only trial.

Magnitude: Not quantified in available studies. No controlled trial of Mexidol alone has reported a performance figure.

Speculative 🟨

Extended Lifespan

Courses in drinking water lengthened lifespan and preserved memory and coordination in aging male rats (Voronina, 2020). No human data exist; basis is animal only.

Brain Mitochondrial Renewal

In young and aging rats, Mexidol raised markers of new mitochondria formation, including PGC-1α (a master regulator of mitochondrial production) (Kirova et al., 2020). Basis is animal only.

Benefit-Modifying Factors

  • Genetic polymorphisms: No study has examined gene variants affecting response. Variation in UGT enzymes (liver enzymes that attach glucuronic acid for excretion) could theoretically alter exposure.
  • Baseline biomarkers and severity: In pooled stroke data, the benefit on neurological scores was larger when the initial deficit was more severe (Voznyuk et al., 2023); people with normal cognition are untested.
  • Sex differences: No sex-specific analysis has been published; MEMO enrolled about 75% women (Zakharov et al., 2022).
  • Pre-existing conditions: In an EPICA sub-analysis, stroke patients with diabetes also gained in daily activity and quality of life versus placebo (Stakhovskaya et al., 2020); no comparison with non-diabetic patients was reported.
  • Age: Cognitive gains appeared in 40–60 and 61–75-year subgroups of MEMO; the 76–90 group had only 13 people (Zakharov et al., 2022). Stroke benefit did not differ by age group (Stakhovskaya et al., 2020).

Potential Risks & Side Effects

Across placebo-controlled trials, overall adverse-event rates were no higher than with placebo: 23% in both groups in MIR (Shamalov et al., 2025) and 19 of 159 versus 32 of 159 participants in MEMO (NCT06834490).

High 🟥 🟥 🟥

No risk reaches High: specific adverse events are documented only in manufacturer-sponsored placebo-controlled trials (MEMO, MIR) and in label post-marketing listings, with no independent replication.

Medium 🟥 🟥

Allergic Skin and Airway Reactions ⚠️ Conflicted

The label lists very rare urticaria (hives) and angioedema (deep swelling of lips, tongue or throat) (Mexidol FORTE 250 prescribing information (Vidal)), plus anaphylactic shock (a life-threatening whole-body allergic reaction) for the injection (Mexidol injection prescribing information (Vidal)). In the MEMO RCT, itching of the throat or nose, sneezing and rash occurred only in the Mexidol arm (Fedin et al., 2021), whereas the MIR RCT posted no excess of skin reactions (NCT06437626). Net reading: a small allergic signal in one trial that the second trial did not reproduce.

Magnitude: MEMO: itchy throat 4 of 159 versus 0 of 159 on placebo; itchy nose 2 versus 0; rash 1 versus 0; sneezing 1 versus 0 (NCT06834490); MIR: skin exfoliation 1 of 152 versus 0 of 152, dermatitis 0 versus 1 (NCT06437626).

Low 🟥

Gastrointestinal Upset and Taste Change ⚠️ Conflicted

The label lists very rare nausea, heartburn and diarrhea (Mexidol FORTE 250 prescribing information (Vidal)). Dyspepsia (indigestion), nausea and dysgeusia (altered taste) were slightly more frequent than placebo in MEMO (Fedin et al., 2021), but similar in both arms in MIR (NCT06437626). Net reading: at most a small, non-significant excess.

Magnitude: MEMO: dyspepsia 2 of 159 versus 1 of 159 on placebo; nausea 1 versus 0; dysgeusia 2 versus 0 (NCT06834490); MIR: diarrhea 2 of 152 versus 1 of 152, dyspepsia 1 versus 0, epigastric (upper-abdominal) discomfort 1 versus 0, upper abdominal pain 0 versus 1, constipation 0 versus 1 (NCT06437626).

Drowsiness, Headache and Dizziness ⚠️ Conflicted

The label lists very rare drowsiness and headache, advising care when driving (Mexidol FORTE 250 prescribing information (Vidal)). In MEMO, dizziness was no more common than placebo (Fedin et al., 2021), while MIR posted slightly more headache with Mexidol (NCT06437626). Net reading: no dizziness excess; a small, unconfirmed headache excess.

Magnitude: MEMO: dizziness 1 of 159 versus 2 of 159 on placebo, no drowsiness or headache events listed (NCT06834490); MIR: headache 5 of 152 versus 2 of 152, insomnia 2 versus 0 (NCT06437626).

Infusion-Rate Reactions with Intravenous Use ⚠️ Conflicted

The injection label lists very rare, brief blood-pressure changes, dizziness, dry cough, throat irritation, chest discomfort and breathing difficulty that may reflect overly fast administration (Mexidol injection prescribing information (Vidal)). In MIR, which began with infusions, adverse events matched placebo (Shamalov et al., 2025). Net reading: rare and rate-related.

Magnitude: MIR: blood pressure increased 3 of 152 versus 5 of 152 on placebo; blood pressure decreased 1 versus 1; dyspnea (breathing difficulty) 1 versus 0 (NCT06437626).

Speculative 🟨

Unknown Safety of Continuous Long-Term Use

Controlled exposure has not exceeded about 3 months; no human data exist on years of continuous use, the pattern longevity users might adopt. Basis is absence of data.

Monoamine Oxidase Effects

A review proposes MAO-A inhibition and MAO-B (monoamine oxidase B, an enzyme that breaks down dopamine) stimulation (Volchegorskii et al., 2023). Possible harms: added serotonin effects with antidepressants and oxidative stress. Basis is mechanistic only.

Risk-Modifying Factors

  • Genetic polymorphisms: No data link gene variants to side effects. Because clearance relies on liver enzymes that attach glucuronic acid, slower-acting variants (for example in UGT genes) could theoretically raise exposure.
  • Baseline liver and kidney function: The label contraindicates use in acute liver or kidney dysfunction; impaired clearance would plausibly raise drug levels (Mexidol FORTE 250 prescribing information (Vidal)).
  • Sex differences: No sex-specific safety analysis exists; pregnancy and breastfeeding are contraindicated for lack of data (Mexidol FORTE 250 prescribing information (Vidal)).
  • Pre-existing conditions: Drug allergies raise hypersensitivity risk; lactose intolerance rules out tablets (Mexidol FORTE 250 prescribing information (Vidal)); asthma with sulfite sensitivity risks severe hypersensitivity and bronchospasm (sudden airway narrowing) with the injection (Mexidol injection prescribing information (Vidal)).
  • Age: In stroke trials, side-effect frequency did not differ across age groups up to 90 years (Stakhovskaya et al., 2020); older adults on several sedating drugs face more additive drowsiness.

Key Interactions & Contraindications

  • Benzodiazepines (diazepam, alprazolam, lorazepam): Caution. The label states Mexidol strengthens their effect, risking added sedation and slowed reactions; the label notes their doses may be reduced (Mexidol FORTE 250 prescribing information (Vidal)).
  • Antidepressants (sertraline, fluoxetine, amitriptyline): Monitor. The label reports a strengthened antidepressant effect that may allow lower antidepressant doses (Mexidol FORTE 250 prescribing information (Vidal)); an open study adding Mexicor to SSRIs found fewer, not more, adverse events (Medvedev et al., 2023).
  • Antiepileptic drugs (carbamazepine, valproate, lamotrigine): Monitor. The label reports enhanced effect (Mexidol FORTE 250 prescribing information (Vidal)), which could add sedation; anticonvulsant dosing stays under the prescriber’s supervision.
  • Antiparkinsonian drugs (levodopa, pramipexole): Monitor. The label reports enhanced effect (Mexidol FORTE 250 prescribing information (Vidal)); in 49 Parkinson’s patients, adding Mexidant (a generic) to levodopa therapy reduced levodopa side effects (Fedorova et al., 2012). Dose changes stay with the treating neurologist.
  • Blood-pressure, antiplatelet (clot-preventing), cholesterol and anticoagulant (blood-thinning) drugs (enalapril, amlodipine, clopidogrel, atorvastatin, warfarin): No interaction found. In 454 stroke-trial patients, adverse-event frequency did not change with these co-medications (Shikh et al., 2026).
  • Clot-dissolving drugs (alteplase, tenecteplase): No interaction found in laboratory clot studies; Mexidol did not alter their clot-dissolving activity (Shchulkin et al., 2025).
  • Drugs cleared by CYP3A4 (a liver enzyme that breaks down many drugs; simvastatin, apixaban, tacrolimus): Monitor. In humans, one oral dose raised a urinary CYP3A4-activity marker about 3-fold for 24 hours, possibly lowering their levels; drug levels were not measured (Baranov et al., 2010).
  • Drugs carried by the ABCB1 pump (digoxin, dabigatran): Monitor (theoretical). Mexidol inhibits this pump in cell studies, which could raise gut absorption and blood levels; human data are lacking (Shchulkin et al., 2023).
  • Over-the-counter sedating antihistamines and sleep aids (diphenhydramine, doxylamine): Caution (theoretical). Additive drowsiness and slowed reactions; separating use from driving or skilled tasks limits the consequence.
  • Alcohol: No harmful interaction reported. The label states Mexidol reduces ethanol’s toxic effects (Mexidol FORTE 250 prescribing information (Vidal)); this does not make intoxication safer to drive or work under.
  • Calming supplements (valerian, kava, phenibut, L-theanine): Caution (theoretical). Additive sedation through overlapping GABA effects; starting one agent at a time limits the consequence.
  • Succinate and metabolic-modulator products (agents that shift cellular energy use; succinic acid, Cytoflavin, meldonium): Monitor (theoretical). Overlapping low-oxygen effects are additive; competitive athletes face anti-doping questions, as meldonium is banned (WADA Prohibited List; Jędrejko et al., 2024).
  • Antioxidant supplements (alpha-lipoic acid, N-acetylcysteine, coenzyme Q10): Monitor (theoretical). Overlapping antioxidant actions are additive, with no known harmful consequence; trials compared alpha-lipoic acid with Mexidol but never combined them (Volchegorskii et al., 2008).

Populations who should avoid Mexidol:

Risk Mitigation Strategies

Doses and timings below follow common practice unless cited.

  • Pre-start liver and kidney check: Measuring ALT, AST and creatinine before a course screens out liver or kidney dysfunction, which raises exposure; an ongoing trial excludes enzymes at or above 2 times normal (NCT07575984).
  • Stop at first allergic sign: Hives, itching of throat or nose, rash or facial swelling end use and prompt medical review, preventing progression to angioedema (Mexidol FORTE 250 prescribing information (Vidal)).
  • Slow intravenous infusion: Keeping to the labeled rate of 40–60 drops per minute, or 5–7 minutes for a slow injection, limits brief blood-pressure changes, cough and chest discomfort (Mexidol injection prescribing information (Vidal)).
  • Sedative audit: Reviewing benzodiazepines, sleep aids and calming supplements before starting limits additive drowsiness and slowed reactions.
  • Driving caution in week one: Avoiding driving until response is known prevents accidents from rare drowsiness, as the label advises (Mexidol FORTE 250 prescribing information (Vidal)).
  • Taking tablets with water after meals: Reduces nausea and heartburn.
  • Fixed course length: Limiting courses to 2–8 weeks, as labeled (Mexidol FORTE 250 prescribing information (Vidal)), avoids untested multi-year exposure.
  • Verified product only: Pharmacy-sealed, registered packs avoid contamination and mislabeling risks of grey-market powders.

Therapeutic Protocol

Each dose below is cited to its source; other parameters (timing, cycling, titration steps) reflect common practice unless cited.

  • Label oral course: 250 mg three times daily, maximum 750 mg/day, for 2–8 weeks (Mexidol FORTE 250 prescribing information (Vidal)).
  • Trial sequential regimen: 500 mg intravenously once daily for 14 days (MEMO) or twice daily for 10 days (MIR), then 250 mg orally three times daily for 60 days (Fedin et al., 2021; Shamalov et al., 2025).
  • Lower oral dose: 125 mg three times daily for 4 weeks, as tested for fatigue (Zolotovskaia et al., 2022).
  • Higher oral doses in trials: 500 mg twice daily (1,000 mg/day, above the label maximum) for 60 days after an intravenous course (Chukanova et al., 2015); 600 mg/day of Mexicor added to antidepressants (Medvedev et al., 2023).
  • Competing approaches: Russian neurology favors injection-led courses for diagnosed disease; nootropic users abroad take oral tablets alone without supervision. Neither approach has been tested for healthy aging.
  • Origin of the approach: Developed and characterized at Moscow’s Zakusov Institute of Pharmacology (Voronina, 2009); sequential courses were popularized through Pharmasoft-sponsored trials.
  • Half-life and dose splitting: Oral half-life is 2–2.6 hours (Mexidol FORTE 250 prescribing information (Vidal)), so the daily amount is split into three doses rather than taken once.
  • Time of day: The label gives no timing; common practice spreads doses across waking hours with the last before early evening, since insomnia appears among overdose symptoms (Mexidol FORTE 250 prescribing information (Vidal)).
  • Genetic polymorphisms: No gene-based dosing guidance exists; slower liver-enzyme variants are a theoretical reason to start with 125 mg tablets, the lower dose tested for fatigue (Zolotovskaia et al., 2022).
  • Sex differences: The label dose is identical for both sexes (Mexidol FORTE 250 prescribing information (Vidal)); no sex-specific dose-response data exist.
  • Age: The label permits use in older adults (Mexidol FORTE 250 prescribing information (Vidal)); MEMO enrolled people up to 90 (Fedin et al., 2021), though very old participants were few.
  • Baseline biomarkers: Normal liver and kidney tests are a prerequisite; larger stroke benefits occurred with worse baseline deficits (Voznyuk et al., 2023).
  • Pre-existing conditions: Stroke patients with diabetes also benefited versus placebo (Stakhovskaya et al., 2020); lactose intolerance rules out tablets.

Discontinuation & Cycling

Sourcing and Quality

  • Registered pharmacy products: The originator is Mexidol/Mexidol FORTE 250 (Pharmasoft); listed generics include Mexiprim, Neurox, Medomexi, Neuromexol and Armadin Long (Mexidol FORTE 250 prescribing information (Vidal)).
  • Generic equivalence: In rabbits, Mexiprim was absorbed less quickly and completely than Mexidol, though elimination was similar (Shchul’kin et al., 2014); human bioequivalence data (studies showing a generic reaches the same blood levels as the original) are not published in English.
  • Grey-market powders: Emoxypine appears as an unauthorized ingredient in nootropic supplements sold online (Jędrejko et al., 2023); identity, dose and purity are unverified.
  • What to look for: Sealed packs bearing a national registration number, an expiry date and an intact leaflet; for powders, a batch-specific certificate of analysis from an independent laboratory.
  • Form and salt: Mexidol is the succinate salt; plain emoxypine (emoxipin) is a different product; tablets contain lactose (Mexidol FORTE 250 prescribing information (Vidal)).

Practical Considerations

  • Time to effect: In the MEMO brain-ischemia trial, differences from placebo appeared by the end of the 14-day intravenous phase and widened by day 75 (Fedin et al., 2021).
  • Common pitfalls: Treating disease-trial results as healthy-aging evidence; buying unverified powders; stacking with sedatives; expecting an immediate single-dose “nootropic” effect.
  • Regulatory status: Prescription-only in Russia (Mexidol FORTE 250 prescribing information (Vidal)); outside the region it is an unapproved pharmaceutical (Jędrejko et al., 2023).
  • Anti-doping status: Not on the World Anti-Doping Agency list (WADA Prohibited List), though a review argues it merits consideration (Jędrejko et al., 2024).
  • Access: Inexpensive in Russia but difficult to obtain legally elsewhere, which pushes users toward unverified sources.

Interaction with Foundational Habits

  • Sleep: Mostly neutral to indirect. The label cites restored sleep-wake cycles in stressed animals, yet lists rare drowsiness and, in overdose, insomnia (Mexidol FORTE 250 prescribing information (Vidal)). Practical consideration: common practice places the last dose before evening, and sleep latency is tracked during the first week.
  • Nutrition: None known; no nutrient depletion reported. Tablets are taken with water; lactose excipient matters for lactose-intolerant users. Alcohol: the label claims reduced ethanol toxicity (Mexidol FORTE 250 prescribing information (Vidal)), but abstinence during a course avoids additive sedation.
  • Exercise: Potentiating (theoretical). Its low-oxygen and succinate actions overlap with banned metabolic modulators, and Russian athletes have used it (Jędrejko et al., 2024). Practical consideration: anti-doping status is relevant for tested competitors; no trial shows effects on training adaptation.
  • Stress management: Potentiating. Clinician-rated anxiety fell faster in alcohol withdrawal (Volchegorskii et al., 2021), and in old rats given dexamethasone (a synthetic stress hormone) it raised suppressed brain stress-hormone receptor gene expression (Terekhina & Kirova, 2025). It complements, not replaces, behavioral stress practices.

Monitoring Protocol & Defining Success

Baseline testing before a first course establishes whether liver and kidney function allow safe use and records a starting point for the outcomes Mexidol is expected to change. It covers ALT, AST and serum creatinine (a blood marker of kidney function), a fasting lipid panel, and a cognitive baseline with the Montreal Cognitive Assessment administered by a clinician or trained tester. A brief anxiety questionnaire and a sleep and fatigue diary for one week complete the baseline.

Ongoing monitoring follows a fixed cadence: liver and kidney tests at 4 weeks and at the end of each course, lipids at the end of each course, and cognitive and anxiety scores at the end of each course and before any repeat course, typically every 6–12 months. Allergy symptoms and drowsiness are reviewed daily during the first week.

Biomarker Optimal Functional Range Why Measure It? Context/Notes
ALT 7–56 U/L (standard reference range) Safety check; rise stops use Lab ranges vary; an ongoing trial excludes values at or above 2 times the upper limit of normal (NCT07575984); no fasting needed
AST 10–40 U/L (standard reference range) Safety check; rise stops use Best paired with ALT; recent heavy exercise can raise AST
Serum creatinine 0.6–1.3 mg/dL (standard reference range) Safety check; rise stops use An ongoing trial excludes creatinine clearance below 50 mL/min (NCT07575984); dehydration can raise the value
LDL cholesterol No established target for this use; track change from own baseline Expected to change (label claim) Fasting sample; the cholesterol claim rests on one small placebo-controlled trial (Klebanova et al., 2006) and a narrative review of post-stroke studies (Zhuravleva et al., 2020)
Montreal Cognitive Assessment score No established target; track change from own baseline Expected to change Alternate test versions limit practice effects; trials measured about 2-point gains in people with impairment (Zakharov & Vakhnina, 2024)

Qualitative markers:

  • Sleep quality and time to fall asleep
  • Daytime alertness versus drowsiness
  • Anxiety and sense of calm under stress
  • Mental fatigue and stamina for focused work
  • Itching, rash or swelling (stop signal)

Emerging Research

  • Hyperacute stroke imaging trial: NCT07575984, Pharmasoft-sponsored, open-label, Phase 4, 120 participants; primary endpoint brain-infarct volume (size of the stroke-damaged area) on magnetic resonance imaging at day 11 versus glycine; recruiting, completion expected April 2027. A positive result adds imaging support to the stroke benefit; a null result weakens the tissue-protection explanation.
  • Older adults with vascular cognitive impairment: NCT07700615, Pharmasoft-sponsored, open-label, 120 adults aged 75 or older, primary endpoint change in Montreal Cognitive Assessment versus standard therapy; completed November 2025, no results posted.
  • Glaucoma dose-ranging trial: NCT06903156, double-blind Phase 2, 102 participants, primary endpoint visual-field mean deviation; completed September 2023, no registry results, but its design matches the trial published by Egorov et al. (2025): less progression than placebo at both doses; cited in the glaucoma item.
  • Glaucoma mitochondrial study: NCT06437639, open-label Phase 4, 80 participants, mitochondrial dysfunction endpoints; completed February 2024, no registry results, but its design matches the study published by Vlasova et al. (2024): mitochondrial enzyme activity and retinal measures improved at 14 and 56 days; cited in the glaucoma item.
  • Rehabilitation after acute brain injury: NCT06221826, Pharmasoft-sponsored, completed 2023 with posted results, published by Belkin et al. (2024): no cognitive difference, lower anxiety; cited in the cognition and anxiety items.
  • Independent replication: Every placebo-controlled trial is Russia-based and mostly sponsor-funded; an independent trial elsewhere, as a review urges (Gupta et al., 2022), could strengthen or overturn current grades.
  • Healthy aging: Only rat lifespan and mitochondrial data exist (Voronina, 2020); a trial in cognitively normal older adults would directly test the longevity case, for or against.
  • Anti-doping review: A review argues for evaluating Mexidol as a performance enhancer (Jędrejko et al., 2024); listing would restrict competitive athletes.

Conclusion

Mexidol is a Russian prescription medicine that combines an antioxidant related to vitamin B6 with succinic acid, a natural energy compound. It is used in Russia mainly after stroke, for long-term reduced blood flow to the brain, for anxiety and for alcohol withdrawal.

The strongest human evidence concerns people who already have brain blood-flow disease. In that group, courses given first by intravenous infusion and then as oral tablets were linked to better recovery after stroke and to small gains in memory and thinking, although some trials found no thinking benefit. Several trials also found less anxiety and fatigue, and smaller studies point to fewer chest-pain attacks in heart disease, better blood sugar control and fewer nerve symptoms in diabetes, and slower glaucoma worsening. Nothing comparable exists for healthy adults: the case for slower aging rests on animal studies alone.

Side effects in trials were uncommon and similar overall to placebo, with mild allergic itching, rash and stomach upset the clearest signals. It can strengthen sedatives and calming medicines, and its safety over years of continuous use is unknown.

The quality of the evidence is the central issue. Most placebo-controlled trials were paid for by the manufacturer and run by an overlapping network of Russian investigators, with little independent replication elsewhere. For health-focused adults without brain blood-flow disease, Mexidol therefore remains a plausible but unproven option whose benefits are inferred from patients, whose product quality outside Russia is uncertain, and whose legal status abroad is unapproved.

Top - Benefits - Risks - Protocol